Casey joins A&P’s board
MONTVALE, N.J. Grocer A&P has announced the election of Thomas Casey to its board of directors.
Casey has more than 24 years of experience in financial management and strategic planning. During his career, he has served as a strategic financial adviser to companies in the retail entertainment, food and drug, convenience store, food wholesale and foodservice industries. During his tenure at Deutsche Bank Securities, Casey was responsible for the banks’ retail industry relationships in North America. He also has held financial and investment banking positions with Citigroup, Merrill Lynch, Blockbuster and Dillon Read & Co.
“I would like to welcome Tom to the board. We are excited to have his extensive financial knowledge and experience to help us lead our comprehensive turnaround. I am looking forward to working with Tom and the board of directors to create value for our shareholders,” stated Christian Haub, executive chairman of the company.
Toys ‘R’ Us unveils must-have toys for the holidays
WAYNE, N.J. Toys “R” Us on Tuesday released its 2010 Holiday Hot Toy List, featuring items from such toy titans as Fisher-Price, Hasbro and Mattel.
The top 15 toys that should be on everyone’s wish list this year include Cuponk and Nerf N-Strike Stampede ECS from Hasbro; Imaginext Bigfoot the Monster and Disney-Pixar “Toy Story 3” Imaginext Tri-County Landfill from Fisher-Price; and Loopz, Monster High, Cleo DeNile and Deuce Gorgon doll set, as well as Sing-a-ma-jigs! from Mattel.
“The Toys ‘R’ Us merchant team has shopped the world to create a list of the 36 top toys guaranteed to delight kids of every age this Christmas season,” said Karen Dodge, SVP and chief merchandising officer for Toys “R” Us U.S. “Each of the items on the 2010 Toys ‘R’ Us Holiday Hot Toy List represents a combination of quality and value, offering children toys they can enjoy for years to come, while providing parents with a selection of products at a variety of price points that can fit any budget.”
FDA advisory committee recommends approval of BI’s atrial fibrillation drug
RIDGEFIELD, Conn. A Food and Drug Administration advisory committee has recommended approval of a drug for patients with atrial fibrillation.
The FDA cardiovascular and renal drugs advisory committee voted unanimously to recommend approval for Boehringer Ingelheim’s Pradaxa (dabigatran etexilate), for preventing strokes in atrial fibrillation patients. For the last 50 years, warfarin has been the only oral anticoagulant drug available for this purpose.
An estimated 2.3 million Americans have atrial fibrillation, and the prevalence is expected to increase to 5.6 million by 2050, according to a 2001 study published in the Journal of the American Medical Association.
An FDA advisory committee recommendation doesn’t guarantee approval for a drug, but is taken into account when the agency decides whether or not to grant approval.